Physician
Salem, Nahla
Salem, Nahla was paid $8.12M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
33Billing provider infoSALEM, NAHLA
HUNTINGTON BEACH, CA 92647
HUNTINGTON BEACH, CA 92647
33aNPI1437368511assigned 05/22/2007
33bProvider typeFamily Medicine Physician
28Total paid$8.12M
24GClaims182,357
24DCodes billed60
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#47 of 2,511
Median peer was paid$13K
This provider vs. median632×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,614 | $1.04M | |
| 2019 | 31,614 | $1.46M | |
| 2020 | 25,784 | $1.11M | |
| 2021 | 34,503 | $1.45M | |
| 2022 | 44,720 | $1.97M | |
| 2023 | 18,414 | $887K | |
| 2024incomplete | 2,708 | $200K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 52,690 | 41,750 | $3.61M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 27,463 | 23,112 | $1.96M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 15% | 15,801 | 14,935 | $1.20M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.3% | 8,577 | 6,268 | $593K |
| 15780 | 3.1% | 438 | 304 | $252K | |
| 96156 | 1.6% | 2,176 | 2,128 | $130K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.4% | 1,493 | 1,439 | $117K |
| 99070 | <1% | 8,186 | 7,366 | $41K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 174 | 172 | $22K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 208 | 208 | $20K |
| G9920 | Screening performed and negative | <1% | 595 | 593 | $20K |
| 93000 | <1% | 2,534 | 2,470 | $19K |
48 more codes
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,209 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 553 | $18K |
| 99385 | <1% | 231 | $18K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,410 | $11K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,693 | $10K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 80 | $9K |
| 90674 | <1% | 281 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,511 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,652 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 577 | $5K |
| 96150 | <1% | 311 | $4K | |
| 96151 | <1% | 277 | $3K | |
| 99386 | <1% | 100 | $3K | |
| 99496 | <1% | 14 | $3K | |
| 90656 | <1% | 94 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15,278 | $2K |
| 90686 | <1% | 59 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 141 | $1K |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 32 | $1K |
| 81002 | <1% | 7,672 | $624.54 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 34 | $582.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 167 | $543.24 |
| 81025 | <1% | 3,183 | $493.20 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 834 | $440.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 31 | $430.44 |
| 69210 | <1% | 130 | $402.70 | |
| 97602 | <1% | 659 | $276.69 | |
| 99000 | <1% | 1,376 | $222.26 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 52 | $200.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 33 | $199.04 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,150 | $135.60 |
| 99354 | <1% | 14 | $134.94 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 856 | $128.95 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,845 | $49.40 |
| 86769 | <1% | 1,103 | $44.61 | |
| 36416 | <1% | 1,039 | $35.34 | |
| 81000 | <1% | 68 | $30.27 | |
| 82962 | <1% | 317 | $22.14 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,044 | $13.24 |
| 69209 | <1% | 66 | $11.54 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 491 | $0.01 |
| 57410 | 0% | 26 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 12 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 19 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 14 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 220 | $0.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 41 | $0.00 |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.